MolecularHealth has its finger on the pulse – personalized medicine as the main theme of the 2014 Hauptstadtkongress conference
The 2014 Hauptstadtkongress for Medicine and Health took place between June 25th and 27th and focused on personalized medicine. The main theme of the Berlin conference thus reflected the primary goal of MolecularHealth: progress and innovation in the area of personalized medicine.
HEIDELBERG, Germany & THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth and innovation in the area of personalized medicine for cancer patients were high on the agenda at this year's Hauptstadtkongress conference in Berlin. Delivering the opening speech at the conference, Professor Dr. Dr. h. c. Otmar D. Wiestler, Director of the German Cancer Research Center (DKFZ), explained how cancer is a genetic disease and how this realization enables new methods in diagnosis and treatment. Today, thanks to the comprehensive characterization of a patient's personal genome, a substantial number of efficient therapeutic options is available. Wiestler started by providing visitors to the conference with an introduction to the principles of personalized medicine. Based on this foundation and the latest knowledge from genome research, MolecularHealth developed its medical device, TreatmentMAP™.
“a small number of genetic changes can be sufficient for cancer to develop.”
TreatmentMAP™ compares patient-specific information from the tumor's genetic makeup with globally available biomedical knowledge and supplies comprehensive molecular profiling of the cancer genome as the basis for determining individualized treatment options. This takes place using data from next generation sequencing. TreatmentMAP™ provides the physician treating the patient with a reliable decision-making platform for the assessment of molecular patient information with regard to the choice of medication.
The opening sequence of the event also saw the Federal Health Minister Hermann Gröhe talk, among other things, about assuring the quality of healthcare as well as the new opportunities and benefits offered by technical developments in the medical field. Medical devices like TreatmentMAP™ ensure that these benefits can be utilized effectively and practically.
Provided specifically for the central theme, the conference's topic forum on molecular medicine offered a discussion and presentation platform that was met with great interest among participants. Dr. Stephan Brock, CEO of Molecular Health GmbH, stated in his presentation how "the classification of evidence from treatment of the individual patient is of great importance." Physicians are faced with the considerable challenge of keeping this evidence and associated analysis up to date with the current status of medical research. TreatmentMAP™ assists physicians in selecting a treatment and provides an objective list of all available scientific and medical data that supports this decision.
Professor Dr. Christof von Kalle, Director of the National Center for Tumor Diseases (NCT) in Heidelberg, explained how even "a small number of genetic changes can be sufficient for cancer to develop." The experts stressed the importance of using a personalized approach in order to consider the genetic roots of the cancer when making a treatment decision, because two patients with the same type of cancer often suffer from two completely different diseases.
TreatmentMAP™ is simple to use in practice: A physician who is trained and certified to use TreatmentMAP™ orders the sequencing of a tumor sample from a qualified sequencing laboratory. After the tissue samples are sequenced, the data collected, together with the patient's clinical data, is integrated and analyzed at MolecularHealth for tumor profiling. From this data, the certified physician creates a report of the findings that provides the patient’s physician with a qualified and individualized recommendation for treatment.
A large-scale study is currently being planned that will include patients of all entities and will classify them not only according to cancer type, but also based on other factors such as age and metastasis status.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAP™ is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.